CDX2 and prostate carcinoma: The Cdx2 polymorphism has been associated with risk for bone fracture [27,28] and with risk for prostate cancer in 25(OH)D deficient men [29]; the VDR-5132 polymorphism has been related to risk for prostate cancer [25].